The Hard Business of Stem Cell Economics and Patient Needs
Premature clinical trial shutdown?
Implications for California stem cell agency
The vagaries of Big Pharma and development of stem cell therapies -- plus the frustrations of a prominent Stanford researcher -- were the topic this week in a major California newspaper.
Irv Weissman, Stanford photo
The researcher is Irv Weissman, head of the stem cell program a…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.